Covis Pharma US, Inc. 401(k) Plan
ERISA Form 5500 plan record drawn from DOL EBSA — verify with linked source filings below.
Sponsored by Covis Pharma US, Inc. · Pennsylvania · Professional & Technical Services
What the 2023 filing shows
Covis Pharma US, Inc. 401(k) Plan holds $9M for 134 participants — about $68,398 per participant, down 9.7% over the 2023 plan year.
- $9M
- total plan assets (2023 EOY)
- 134
- covered participants
- $68,398
- avg assets per participant
- -9.7%
- assets change YoY
The plan reported a net loss of $987K for the year — a single-year figure driven by markets and benefit payments, not a measure of plan health.
What the Filing Says About Covis Pharma US, Inc. 401(k) Plan
Covis Pharma US, Inc. 401(k) Plan is a 401(k) retirement plan sponsored by Covis Pharma US, Inc., headquartered in Pennsylvania. As of the 2023 Form 5500 filing, the plan reports $9M in total end-of-year assets and covers 134 participants across the Professional & Technical Services industry. The sponsor's EIN on file with the U.S. Department of Labor is 845171883, and the plan has been effective since 2020-08-01. Its filing status is currently FILING RECEIVED.
Year over year, total assets moved from $10M at the beginning of 2023 to $9M at year-end — a decline of 9.7%. Net assets (after liabilities) closed the year at $9M, with reported net income of $-986,960 driven by investment returns, contributions received, and benefit payments during the period. These figures reflect what the plan administrator certified on Schedule H or Schedule I of the Form 5500 annual return and can be compared against 2 prior plan-year filings from the same sponsor shown below.
Asset totals and participant counts reflect a single plan year snapshot and can change materially with market conditions, plan mergers, or workforce changes. Fields such as "net income" include both realized investment performance and contribution/distribution flows — a single-year figure does not by itself indicate plan health or participant outcomes. This page summarizes public DOL disclosures for research and educational purposes only and is not retirement, tax, legal, or financial advice. Before making decisions about your own retirement benefits or evaluating an employer's plan, verify the underlying filing directly via the DOL EFAST2 system and consult a qualified professional.
Financial Summary (2023)
| Total Assets (Beginning of Year) | $10M |
| Total Assets (End of Year) | $9M |
| Net Assets (End of Year) | $9M |
| Net Income | $-986,960 |
| Plan Type | 401(k) |
| Employer EIN | 845171883 |
| Plan Effective Date | 2020-08-01 |
| Filing Status | FILING RECEIVED |
Sponsor Plan History (Covis Pharma US, Inc.)
| Year | Plans | Participants | Total Assets |
|---|---|---|---|
| 2022 | 1 | 157 | $10M |
| 2023 | 1 | 134 | $9M |
| 2024 | 1 | 64 | $10M |
Nearby 401(k) Plans in Pennsylvania
Peer 401(k) plans — same state, same plan type — ranked by total assets.
- Comcast Corporation Retirement - Investment Plan $17.4B · 93,136
- Cigna 401(k) Plan $13.0B · 66,760
- The Vanguard Retirement and Savings Plan $9.8B · 18,200
- The Bank of New York Mellon Corporation 401(k) Savings Plan $9.0B · 25,184
- Gsk 401(k) Plan $8.1B · 11,837
Related Data
Guides
Frequently Asked Questions
How much money is in the Covis Pharma US, Inc. 401(k) Plan? ▼
What type of plan is Covis Pharma US, Inc. 401(k) Plan? ▼
Who sponsors the Covis Pharma US, Inc. 401(k) Plan? ▼
How did Covis Pharma US, Inc. 401(k) Plan perform in 2023? ▼
Where can I find official filings for Covis Pharma US, Inc. 401(k) Plan? ▼
How does Covis Pharma US, Inc. 401(k) Plan compare to other plans? ▼
Explore PlainRetire
Source: U.S. Department of Labor, Employee Benefits Security Administration (EBSA), Form 5500 public disclosure dataset. Plan year 2023.
Source: DOL EFAST2 filing system (efast.dol.gov) — original filing retrieval by EIN 845171883.
Reference: IRS Publication 560 — Retirement Plans for Small Business, contribution-limit rules.
Reference: IRS Publication 590-B — Distributions from IRAs, RMD rules under SECURE Act 2.0.
Read our methodology — how this data is sourced, computed, and verified.